Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.10. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 | 3 | GlobeNewswire (USA) | ||
11.09. | Wells Fargo initiates Milestone Pharmaceuticals stock with Overweight rating | 16 | Investing.com | ||
12.08. | Milestone Pharmaceuticals GAAP EPS of -$0.20 misses by $0.02 | 3 | Seeking Alpha | ||
12.08. | Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
12.08. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update | 351 | GlobeNewswire (Europe) | FDA Accepted the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST... ► Artikel lesen | |
12.08. | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
11.07. | Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development | 5 | RTTNews | ||
MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
11.07. | Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge | 3 | Benzinga.com | ||
11.07. | Why Is Milestone Pharmaceuticals Stock Plunging On Friday? | 1 | Benzinga.com | ||
11.07. | Milestone Pharmaceuticals plunges after pricing $52.5M offering | 3 | Seeking Alpha | ||
11.07. | Milestone Pharmaceuticals prices $52.5 million public offering | 2 | Investing.com | ||
11.07. | Milestone Pharmaceuticals stock plunges on public offering announcement | 4 | Investing.com | ||
11.07. | Kapitalerhöhung angekündigt: Aktie von Milestone Pharmaceuticals bricht ein | 3 | Investing.com Deutsch | ||
11.07. | Milestone Pharmaceuticals proposes capital raise via securities offering | 1 | Seeking Alpha | ||
11.07. | Milestone Pharmaceuticals announces public offering of shares and warrants | 3 | Investing.com | ||
11.07. | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.07. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray | 400 | GlobeNewswire (Europe) | New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone®... ► Artikel lesen | |
17.06. | Milestone Pharmaceuticals resubmits Cardamyst filing after FDA response | 8 | Investing.com | ||
16.06. | Milestone Pharma Announces Submission Of Its Response To CRL Regarding NDA For CARDAMYST | 1 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 27,580 | +0,22 % | Fast 150 % Kurschance! Plug Power, Bayer, Planethic Group Aktie | Bietet sich bei der Planethic Group (vormals Veganz Group) die Kaufchance des Herbstes? Analysten sehen jedenfalls über 100 % Kurspotenzial. Die jüngste Korrektur scheint übertrieben und lockt zum Einstieg.... ► Artikel lesen | |
NOVO NORDISK | 45,850 | -0,40 % | Novo Nordisk und Eli Lilly unter Druck - Trump will massiven Preissturz | Die Aktien von Novo Nordisk und Eli Lilly stehen zum Wochenschluss deutlich unter Druck. Knapp vier beziehungsweise gut vier Prozent geht es bei den Werten auf der Handelsplattform Tradegate am Freitagvormittag... ► Artikel lesen | |
PFIZER | 21,255 | -0,28 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
GILEAD SCIENCES | 102,90 | -1,70 % | Gilead Sciences: Ausbruch mit Ansage! | Die Aktie von Gilead Sciences zählt zu den besten Performern im Pharmasektor und überzeugt mit stabiler Ertragskraft, technischem Aufwärtstrend und positiver Analystenstimmung. Wir hatten vergangenen... ► Artikel lesen | |
MERCK & CO | 75,00 | -0,79 % | 7,25% Vontobel-Aktienanleihe auf Merck & Co, Novartis, Roche: Pharma-Giganten im Wandel - Anleiheanalyse | München (www.anleihencheck.de) - Die globale Pharmaindustrie steht vor einer neuen Ära, geprägt von biotechnologischen Innovationen, steigenden Gesundheitsausgaben und wachsender Nachfrage nach individualisierten... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 362,80 | -1,31 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK at the North American Cystic Fibrosis Conference | - Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly... ► Artikel lesen | |
EYEPOINT PHARMACEUTICALS | 9,692 | -1,72 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
BAUSCH HEALTH | 5,247 | -2,35 % | Bausch Health Companies Inc.: Bausch Health Announces Results of Special Meeting of Shareholders | LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 24,900 | +2,47 % | Assembly Biosciences nach +279% in 6 Monaten: Was ist noch drin? | Mein Top-Favorit 2025 hat mit beeindruckender Stärke ein neues Langzeithoch markiert: Aktien von Assembly Biosciences kosten mittlerweile fast 30 US$, nachdem sie im April noch für 7,75 US$ zu haben... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 10,500 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
NEWRON PHARMACEUTICALS | 15,640 | +2,62 % | NEWRON PHARMACEUTICALS SPA: Jetzt entscheidet sich alles! | ||
ALTIMMUNE | 3,422 | +1,97 % | Altimmune, Inc: Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 | ||
OPKO HEALTH | 1,250 | +1,31 % | Here's Why You Should Add OPKO Health Stock to Your Portfolio | ||
LIGAND PHARMACEUTICALS | 161,00 | +0,62 % | Ligand Pharmaceuticals: Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
JAZZ PHARMACEUTICALS | 119,65 | +0,25 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 | DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5... ► Artikel lesen |